Basilea Pharmaceutica International

Basilea Pharmaceutica is a commercial-stage biopharmaceutical company headquartered in Switzerland, dedicated to developing and commercializing innovative drugs for severe bacterial and fungal infections. The company's portfolio features two flagship products: Cresemba (isavuconazole), an antifungal for invasive aspergillosis and mucormycosis, and Zevtera (ceftobiprole), an antibiotic for serious bacterial infections including MRSA. Basilea has successfully transitioned to a sustainable, profitable business model by leveraging strategic partnerships with global pharmaceutical leaders like Pfizer and Astellas. The company continues to expand its anti-infective pipeline through internal R&D and targeted acquisitions, such as fosmanogepix, to address the growing global threat of antimicrobial resistance.